


I know what I'm made of

Dual-targeted inhibition: CYRAMZA and erlotinib respectively target VEGF and EGFR signaling pathways for a synergistic effect on suppressing tumor growth⁶⁻⁸

CYRAMZA binds to VEGFR2 and blocks multiple ligands from binding^{6,8-11*}



CYRAMZA and erlotinib respectively target the VEGF and EGFR signaling pathways, which are known to play a critical role in tumor growth, metastasis, and angiogenesis⁶⁻⁸

*As demonstrated in nonclinical studies, CYRAMZA inhibited angiogenesis in an in vivo animal model.⁹

Diagram not drawn to scale.

mTOR=mammalian target of rapamycin; PI3K=phosphoinositide-3-kinase; RAF=rapidly accelerated fibrosarcoma; VEGF=vascular endothelial growth factor; VEGFR2=vascular endothelial growth factor receptor 2.